Literature DB >> 6194983

Inhibition of phospholipase A2 by gabexate mesilate, camostate and aprotinine.

J Freise, P Magerstedt, K Schmid.   

Abstract

Gabexate mesilate (FOY, ethyl-p-[6-guanidino-hexanoyloxy]-benzoate-methanesulfonate), camostate (N,N-dimethyl-carbamoylmethyl-4-[4-guanidinobenzoyloxy]-phenylacetate), methanesulfonate (FOYPAN) and aprotinine (Trasylol) were tested for possible inhibition of phospholipase A2. Gabexate mesilate at a concentration of 5 x 10(-4) mol/l and camostate at a concentration of 10(-3) mol/l caused a 50% reduction in enzyme activity. There was no inhibition by aprotinine at clinical doses; 40 million KIU/l were necessary to reduce phospholipase A2 activity by 20%.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194983     DOI: 10.1159/000469576

Source DB:  PubMed          Journal:  Enzyme        ISSN: 0013-9432


  4 in total

1.  Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study.

Authors:  P Pederzoli; G Cavallini; M Falconi; C Bassi
Journal:  Int J Pancreatol       Date:  1993-10

2.  Inhibition of porcine pancreas phospholipase A2 activation by gabexate mesilate.

Authors:  H R Schädlich; M Büchler; H G Beger
Journal:  Klin Wochenschr       Date:  1989-02-01

Review 3.  Pulmonary and generalized lysosomal storage induced by amphiphilic drugs.

Authors:  Z Hruban
Journal:  Environ Health Perspect       Date:  1984-04       Impact factor: 9.031

Review 4.  Experimental pancreatic hyperplasia and neoplasia: effects of dietary and surgical manipulation.

Authors:  P Watanapa; R C Williamson
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.